Tevogen Bio Appoints Cell Therapy Expert Dr. Dolores Grosso as Global Clinical Development Lead to Accommodate Its Expanding Portfolio

• Dr. Grosso will develop and implement the company’s expanding clinical trial agenda.
• Tevogen’s cell therapy research pipeline focuses on virology, neurology, and oncology.
• Tevogen is reported as the highest valued tech startup of 2022.

Tevogen Bio, a late-stage clinical biotechnology company specializing in the development of cellular immunotherapies in virology, neurology, and oncology today announced the appointment of Dr. Grosso to lead the development and implementation of the company’s expanding clinical trial portfolio.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230104005931/en/

Dr. Dolores Grosso, Global Clinical Development Lead, Tevogen Bio (Photo: Business Wire)

Dr. Grosso has spent more than 40 years in health care, the first 15 years as a critical care nurse at Thomas Jefferson University in Philadelphia. She earned a Master of Science degree in 1986 and a Post Master’s Nurse Practitioner degree in 1995, both in Critical Care Nursing, from the University of Pennsylvania. In 1996, she joined the Blood and Marrow Transplant Program as a Nurse Practitioner at Thomas Jefferson University.

Over the next 25 years, Dr. Grosso expanded her career in cellular therapy research under the mentorship of acclaimed oncologist, Professor Neal Flomenberg, M.D. In 2009, she earned a Doctor of Nursing Practice investigating donor selection strategies in haploidentical hematopoietic stem cell transplantation at Thomas Jefferson University. Later that year, she was appointed to the faculty of Jefferson Medical College, ultimately achieving the rank of Associate Professor in Research in early 2022. Dr. Grosso has written over 20 investigator-initiated research protocols with multiple first and last author publications. She has served as a research mentor to numerous physician fellows including several participating in a Master’s in Pharmacology Program at Jefferson. In 2021, she won the prestigious Excellence in Clinical Research Award from the Sidney Kimmel Cancer Center at Thomas Jefferson University in recognition of her prolific research activities and contributions to the Cancer Center’s clinical research efforts.

“After 40 years caring for patients, I highly value Tevogen Bio’s commitment to developing next-generation affordable immunotherapies,” said Dr. Grosso, “As a researcher, I am excited to participate in the expansion of Tevogen’s precision T cell platform for the novel treatment of disease.”

“Since our foundation in 2020, our advanced science and business models have led us to become one of the most successful start-up biotech companies. As Tevogen’s founder, I am pleased to welcome Dr. Grosso’s unique experience and unwavering passion to our leadership team,” said Tevogen CEO Dr. Ryan Saadi, M.D., M.P.H.

About Tevogen’s Next Generation Precision T Cell Platform

Tevogen’s next generation precision T cell platform is designed to provide increased immunologic specificity to eliminate malignant and virally infected cells, while allowing healthy cells to remain intact. Multiple targets are selected in advance with the goal of overcoming the mutational capacity of cancer cells and viruses which can otherwise allow for escape from immunologic targeting.

Tevogen is investigating its technology’s potential to overcome the primary barriers to the broad application of personalized T cell therapies: potency, purity, production-at-scale, and patient-pairing, without the limitations of current approaches. Tevogen’s goal is to open the vast and unprecedented potential of developing personalized immunotherapies for large patient populations impacted by common cancers and viral infections.

Tevogen announced the completion of patient enrollment in the Proof-of-Concept clinical trial of its lead product, TVGN-489, for ambulatory, acute-risk COVID-19 patients, with no dose-limiting toxicities or significant treatment-related adverse events observed for any patient at any dose level.

TVGN-489 is a genetically unmodified, off-the-shelf, allogeneic cytotoxic CD8+ T lymphocyte (CTL) product with activity against multiple, precise targets across the entire SARS-CoV-2 genome.

About Tevogen Bio

Tevogen Bio is driven by a team of highly experienced industry leaders and distinguished scientists with drug development and global product launch experience. Tevogen’s leadership believes that accessible personalized immunotherapies are the next frontier of medicine, and that disruptive business models are required to sustain medical innovation in the post-pandemic world.

Forward Looking Statements

This press release contains certain forward-looking statements relating to Tevogen Bio™ Inc (the “Company”) and its business. These statements are based on management’s current expectations and beliefs as of the date of this release and are subject to several factors which involve known and unknown risks, delays, uncertainties, and other factors not under the Company’s control that may cause actual results, performance or achievements to be materially different from the results, performance or other expectations implied by these forward-looking statements. Forward-looking statements can sometimes be identified by terminology such as “may,” “will,” “should,” “intend,” “expect,” “believe,” “potential,” and “possible,” or their negatives or comparable terminology, as well as other words and expressions referencing future events, conditions, or circumstances. In any forward-looking statement in which the Company expresses an expectation or belief as to future results, there can be no assurance that the statement or expectation or belief will be achieved. Various factors may cause differences between the Company’s expectations and actual results, including, among others: the Company’s limited operating history; uncertainties inherent in the execution, cost, and completion of preclinical studies and clinical trials; risks related to regulatory review, and approval and commercial development; risks associated with intellectual property protection; and risks related to matters that could affect the Company’s future financial results, including the commercial potential, sales, and pricing of the Company’s products. Except as required by law, the Company undertakes no obligation to update the forward-looking statements or any of the information in this release, or provide additional information, and expressly disclaims any and all liability and makes no representations or warranties in connection herewith or with respect to any omissions therefrom.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230104005931/en/